Nivolumab has shown benefit in combination with chemotherapy in HER2-negative advanced gastric cancer, while pembrolizumab is used in PD-L1-positive tumors and microsatellite instability-high (MSI-H) cancers [123]. The gene discussed is ERBB2; the disease is gastric cancer.